Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarnaâ„¢ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of the…
News
Recent Posts
- No key immune complications reported with experimental cell therapy
- Cell therapy linked to skin improvements in scleroderma trial
- Scleroderma patients open to aesthetic treatments, survey finds
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds